title: Myeloproliferative cancers: treatment prospects for rare diseases.
authors.forename: Vicki
authors.initials: V
authors.lastname: Brower
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics*; D016026:Bone Marrow Transplantation; D002986:Clinical Trials as Topic; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors* / Q000235:genetics*; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000235:genetics* / Q000601:surgery; D009154:Mutation; D009570:Nitriles; D010649:Phenylalanine; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines; D035583:Rare Diseases / Q000188:drug therapy / Q000235:genetics; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014633:Valine
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D016898:Interferon-alpha; D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D010649:Phenylalanine; C540383:ruxolitinib; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D014633:Valine; C100416:peginterferon alfa-2a